| Krishanu Bappa Gupta, MD, PHD | |
|
525 Broad St, Suite 202, Cumberland, RI 02864-6919 | |
| (401) 727-4600 | |
| (401) 727-4690 |
| Full Name | Krishanu Bappa Gupta |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 27 Years |
| Location | 525 Broad St, Cumberland, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003807397 | NPI | - | NPPES |
| 7010331 | Medicaid | RI | |
| 21093-9 | Other | RI | BCBS - RI |
| 16-00084 | Other | RI | UNITED HEALTHCARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD11080 (Rhode Island) | Primary |
| 2085R0202X | Radiology - Diagnostic Radiology | 210605 (Massachusetts) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Radiology, Inc. | 9234140690 | 3 |
| Open Mri Of New England, Inc. | 7012928294 | 3 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting." The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued.
On the heels of the Federal Drug Administration's (FDA) second public workshop to explore the public health considerations associated with e-cigarettes, nonprofit research organization RTI International released a new research paper "Exhaled Electronic Cigarette Emissions: What's Your Secondhand Exposure?," which explores the composition of e-cigarette vapor and the potential health impacts of secondhand exposure.
Physician experts in health system issues propose a timely alternative process for harnessing and supporting physician-led innovations to rapidly address front-line health care delivery problems and improve health.
In a new poll of primary care physicians, nearly half of them said their patients received too much medical care and more than a quarter said they were practicing more aggressively than they'd like to. This could mean ordering more tests, prescribing more drugs or diagnosing people with diseases, although they would never have experienced any symptoms. On the other hand, just six percent of doctors believed their patients were getting too little care.
InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the LipiScan IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound and near-infrared spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events.
› Verified 8 days ago
| Entity Name | Advanced Radiology, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780638494 PECOS PAC ID: 9234140690 Enrollment ID: O20060522000184 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting." The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued.
On the heels of the Federal Drug Administration's (FDA) second public workshop to explore the public health considerations associated with e-cigarettes, nonprofit research organization RTI International released a new research paper "Exhaled Electronic Cigarette Emissions: What's Your Secondhand Exposure?," which explores the composition of e-cigarette vapor and the potential health impacts of secondhand exposure.
Physician experts in health system issues propose a timely alternative process for harnessing and supporting physician-led innovations to rapidly address front-line health care delivery problems and improve health.
In a new poll of primary care physicians, nearly half of them said their patients received too much medical care and more than a quarter said they were practicing more aggressively than they'd like to. This could mean ordering more tests, prescribing more drugs or diagnosing people with diseases, although they would never have experienced any symptoms. On the other hand, just six percent of doctors believed their patients were getting too little care.
InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the LipiScan IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound and near-infrared spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events.
› Verified 8 days ago
| Entity Name | Open Mri Of New England, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053365734 PECOS PAC ID: 7012928294 Enrollment ID: O20060601000302 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting." The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued.
On the heels of the Federal Drug Administration's (FDA) second public workshop to explore the public health considerations associated with e-cigarettes, nonprofit research organization RTI International released a new research paper "Exhaled Electronic Cigarette Emissions: What's Your Secondhand Exposure?," which explores the composition of e-cigarette vapor and the potential health impacts of secondhand exposure.
Physician experts in health system issues propose a timely alternative process for harnessing and supporting physician-led innovations to rapidly address front-line health care delivery problems and improve health.
In a new poll of primary care physicians, nearly half of them said their patients received too much medical care and more than a quarter said they were practicing more aggressively than they'd like to. This could mean ordering more tests, prescribing more drugs or diagnosing people with diseases, although they would never have experienced any symptoms. On the other hand, just six percent of doctors believed their patients were getting too little care.
InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the LipiScan IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound and near-infrared spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Krishanu Bappa Gupta, MD, PHD 525 Broad St, Suite 202, Cumberland, RI 02864-6919 Ph: (401) 727-4600 | Krishanu Bappa Gupta, MD, PHD 525 Broad St, Suite 202, Cumberland, RI 02864-6919 Ph: (401) 727-4600 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting." The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued.
On the heels of the Federal Drug Administration's (FDA) second public workshop to explore the public health considerations associated with e-cigarettes, nonprofit research organization RTI International released a new research paper "Exhaled Electronic Cigarette Emissions: What's Your Secondhand Exposure?," which explores the composition of e-cigarette vapor and the potential health impacts of secondhand exposure.
Physician experts in health system issues propose a timely alternative process for harnessing and supporting physician-led innovations to rapidly address front-line health care delivery problems and improve health.
In a new poll of primary care physicians, nearly half of them said their patients received too much medical care and more than a quarter said they were practicing more aggressively than they'd like to. This could mean ordering more tests, prescribing more drugs or diagnosing people with diseases, although they would never have experienced any symptoms. On the other hand, just six percent of doctors believed their patients were getting too little care.
InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the LipiScan IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound and near-infrared spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events.
› Verified 8 days ago
Dr. David Cheng, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 525 Broad St, Suite 202- Advanced Radiology, Cumberland, RI 02864 Phone: 401-727-4600 Fax: 401-727-4690 | |
Donnella Simone Comeau, MD PHD Radiology Medicare: Accepting Medicare Assignments Practice Location: 525 Broad St, Advanced Radiology, Cumberland, RI 02864 Phone: 401-725-6736 |